Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. AWK

Go back to Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression

Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC

April 23, 2018 10:20 AM EDT

RBC Capital analyst Brian Abrahams sees weakness in Sage Therapeutics (NASDAQ: SAGE) on Friday, related to insider selling and a deal with Biogen for IONS, as a buying opportunity.

"... we view these as non-fundamental, and Friday's detailed, in-line brexanolone data, today's on-track NDA filing,... More